Described herein are cannabinoid formulations for oral administration. Further described herein are methods for orally administering one or more cannabinoids to a subject in need thereof.

A medication of natural Chinese medicine with sustained release for cancer treatment and its preparation method thereof contains active ingredients of: ginsenoside, Astragalus polysaccharide, zedoary (Curcuma zedoaria), river bulrush (Sparganium stolonferum Buch.-Ham), Ternstroemia gymnanthera, Fructus Ligustri Lucidi, licorice, Chinese skullcap (Scutellaria baicalnsis Georgi), Sculellaria barbata, paclitaxel, Silybum marianum (L.) Gaertn., and Cannabidiol (CBD). The drug can restore body balance and promote self-recovery. The drug can be used as an alternative medicine or can be used in combination with conventional cancer treatment, and is especially target for patients suffered from toxic side effects of radiotherapy and chemotherapy, which can increase the efficiency and reduce the toxicity of conventional cancer treatment and eliminate side effects of vomiting, hair loss, and unbearable soreness of the body.

The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the active pharmaceutical ingredient comprises a weakly basic active pharmaceutical ingredient having a solubility of not more than 100 g/mL at pH 6.8.

Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.

A method for preparing a suspension of size-controlled microparticles stabilized by a layer of amphiphilic material. The method, which may be applied to preparations using microfluidic techniques, comprises controlling the temperature of the microparticles during the preparation process and preferably while collecting the formed microparticles.

Stabilized liquid agrochemical compositions are provided that comprise flowable, liquid dispersion concentrates comprising a) a continuous liquid phase; and b) a dispersed phase comprising a dispersion of gel-like polymer matrix particles having a hardness greater than 0.01 MPa and less than 6 MPa, and where the outside surfaces of the particles comprise a colloidal solid material and the particles have a agrochemically active ingredient distributed therein The agrochemically active ingredient may be solid or liquid and is distributed within the polymer matrix particle. The compositions of the invention can be used directly or with dilution to combat pests or as plant growth regulators.

The present invention disclosed a microcapsule modified with nanomaterial for controlled release of active agent comprising; a core comprising active agent and said polymer shell encompassing said core; characterized in that said polymer shell is made up of polymer nanocomposite and a process for the preparation thereof.

Described herein are transdermal formulations of phytocannabinoids and methods of using the same in the treatment of pain and/or inflammation.

The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the active pharmaceutical ingredient comprises a weakly basic active pharmaceutical ingredient having a solubility of not more than 100 g/mL at pH 6.8.

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.